Document:

exv10w29

 

EXHIBIT 10.29

NON-QUALIFIED STOCK OPTION GRANT

For good and valuable consideration, receipt of which is hereby acknowledged, Analogic Corporation,
a Massachusetts Corporation (hereinafter called the “Company”), does hereby grant to NAME
of CITY, STATE, (hereinafter called the “Grantee) as of DATE an option
designated as a Non-Qualified Option to purchase Five Thousand (5,000) shares of Common Stock, of
the par value of $.05 per share, of the Company, pursuant to the terms of the Company’s
Non-Qualified Stock Option Plan for Non-Employee Directors dated January 31, 1997, as Amended
December 8, 2003 (hereinafter called the “Plan”). A copy of the Plan is annexed hereto and is
incorporated herein in its entirety by reference.

The Grantee hereby accepts the Option granted herein subject to all of the provisions of the Plan,
and upon the following additional terms and conditions:

	 	1.  	The price at which the shares of Common Stock may be purchased pursuant to this
Option is PRICE per share, subject to adjustment as provided in the Plan.
	 
	 	2.  	This Option may be exercised by the giving of written notice, in person or by
registered mail, to the Company, marked “Attention: Treasurer”, at its principal place of
business in Peabody, Massachusetts, of the election to purchase shares pursuant hereto,
accompanied by the full purchase price of the shares being so purchased, together with the
amount of any tax or excise due in respect of the sale and issue thereof, in cash or by
certified or bank cashier’s check.

IN WITNESS WHEREOF, ANALOGIC CORPORATION has caused this grant to be signed by its duly authorized
officer and its corporate seal to be hereto affixed this DAY - MONTH in the year

	 	 	 	 	 
	 	 	ANALOGIC CORPORATION
	 
	 	 	 	 
	

	 	By	 	 
	

	 	 	 	 
	

	 	 	 	Its Treasurer

The foregoing option is hereby accepted on the terms and conditions set forth herein, and is
expressly subject to all the provisions set forth in the Analogic Corporation Non-Qualified Stock
Option Plan for Non-Employee Directors dated January 31, 1997, as Amended December 8, 2003, a copy
of which is annexed hereto.

	 	 	 	 	 
	 
	 	 	 	 
	 	 	 
	

	 	 	 	Granteeexv10w30

 

EXHIBIT 10.30

NOTIFICATION OF STOCK OPTION GRANT

For good and valuable consideration, receipt of which is hereby acknowledged, Analogic Corporation,
a Massachusetts Corporation (hereinafter called the “Company”), does hereby grant to NAME
of City, State, Zip (hereinafter called the “Grantee”) an option designated as an Incentive
Stock Option to purchase Amount shares of Common Stock, par value of $.05 per share, of the
Company, pursuant to the terms of the Company’s Key Employee Incentive Stock Option Plan dated June
11, 1998; as amended October 12, 2000 and as amended
November 16, 2001 (hereinafter called the “Plan”). A copy of the Plan is annexed hereto and is
incorporated herein in its entirety by reference.

The Grantee hereby accepts the Option granted herein subject to all of the provisions of the Plan,
and upon the following additional terms and conditions:

	 	1.  	The price at which the shares of Common Stock may be purchased pursuant to
this Option is Price a share, subject to adjustment as provided in the
Plan.	 
	 
	 	2.  	This Option may be exercised by the giving of written notice, in person or by
registered mail, to the Company, marked “Attention: Treasurer”, at its principal
place of business in Peabody, Massachusetts, of the election to purchase shares
pursuant hereto, accompanied by the full purchase price of the shares being so
purchased, together with the amount of any tax or excise due in respect of the
sale and issue thereof, in cash or by certified or bank cashier’s check.	 

IN WITNESS WHEREOF, ANALOGIC CORPORATION has caused this grant to be signed by its duly authorized
officer and its corporate seal to be hereto affixed this Date day of Month in the
year ___.

	 	 	 	 	 
	 	 	ANALOGIC CORPORATION
	 
	 	 	 	 
	

	 	By	 	 
	

	 	 	 	 
	

	 	 	 	Treasurer

     The foregoing Option is hereby accepted on the terms and conditions set forth herein, and is
expressly subject to all the provisions set forth in the Analogic Corporation Key Employee
Incentive Stock Option Plan dated June 11, 1998; as amended October 12, 2000 and as amended
November 16, 2001.

	 	 	 	 	 
	 
	 	 	 	 
	 	 	 
	

	 	 	 	Granteeexv10w31

 

EXHIBIT 10.31

	 	 	 
	Date:
	 	 
	 
	 	 
	To:
	 	 
	 
	 	 
	From:

	 	John J. Millerick
	 
	 	 
	 

NOTIFICATION OF STOCK GRANT

You are hereby notified that
on ___ the Board of Directors of Analogic Corporation voted to
grant to you Amount Shares Common Stock of the Corporation under the Key Employee Stock
Bonus Plan dated October 12, 2000 (the “Plan”), as amended.

In accordance with the terms of this Plan, you are requested to sign the attached Non-Competition
Agreement, following which stock certificates representing the shares of this Grant will be
executed in your name. These certificates will be held in escrow by the Company until such time as
restrictions upon your disposition of these shares shall lapse. The restrictions, as to the first
25% of these shares, shall lapse on ___. For each of the three (3) years then following
___ the restrictions upon disposition of 25% of such shares shall lapse. At the time that
the restrictions upon your disposition of shares shall lapse, under present Internal Revenue
Regulations, certain federal and state income taxes will be due.

Attached hereto is the Plan Prospectus (with the Plan itself attached as Exhibit A). The Plan sets
forth the terms and conditions of this Grant. By signing this document, the recipient agrees to
accept the Grant of the above mentioned shares of Analogic Common Stock in accordance with all
terms and conditions of the Plan.

 

 

Page 2

Please sign each Notification of Stock Grant and the Non-Competition Agreement, keep one copy of
the signed Notification of Stock Grant for your files, and return both a signed Notification of
Stock Grant and the Non-Competition Agreement to:

	 	 	 
	 

	 	John J. Millerick
	

	 	Chief Financial Officer and Treasurer
	

	 	Analogic Corporation
	

	 	8 Centennial Drive
	

	 	Peabody, MA 01960

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	ANALOGIC CORPORATION
	 
	 	 	 	 	 	 	 	 
	Name:

	 	 	 	 
	 	By:	 	 
	

	 	 
	 	 	 	 	 	 
	

	 	 	 	 	 	 	 	John J. Millerick
	

	 	 	 	 	 	 	 	Senior Vice President and
	

	 	 	 	 	 	 	 	Chief Financial Officer

 

 

NON-COMPETITION AGREEMENT

The undersigned, NAME, an employee of Analogic Corporation, a United States corporation
with its principal place of business in Peabody, MA (hereinafter referred to as the “Company”), in
consideration of the transfer of shares of the company’s Common Stock to the undersigned under and
in accordance with the provisions of the Key Employee Stock Bonus Plan dated October 12, 2000, as
amended, and for other good and valuable consideration, the receipt whereof is hereby acknowledged,
hereby covenants and agrees with the Company that, during the period of one (1) year commencing
with the date of the cessation of his employment by the Company, however caused, whether
voluntarily or involuntarily, the undersigned will not accept an identical or substantially similar
position to that held by him at the Company immediately prior to the cessation of his employment
with the Company with any business (including without limitation any business conducted by a
person, firm, association, or corporation) that is directly competitive with the business of the
Company or otherwise have any material investment or interest in any such business.

If the Company shall merge or consolidate with any corporation and the Company shall not be the
surviving corporation or if the Company shall sell or exchange substantially all of its assets, or
if more than 40% of the voting securities of the Company shall be beneficially owned (directly or
indirectly) by any other entity, the obligations of the undersigned to the Company under this
instrument shall ipso facto terminate and be of no further effect whatsoever.

Notwithstanding the provisions of the first paragraph of this Agreement, in the event that the
employment of the undersigned by the Company shall terminate prior to retirement and such cessation
of employment shall in no way be attributable to either the resignation (or other voluntary act) of
the undersigned or the fault (or conduct) of the undersigned, the undersigned may apply to the
Stock Plan Committee (the “Committee”) appointed to administer the aforesaid Stock Bonus Plan for a
termination of the obligations of the undersigned under this instrument, and, in such event, upon a
determination by the Committee that such cessation of employment of the undersigned was in no way
attributable to either the resignation (or other voluntary act) of the undersigned or the fault (or
conduct) of the undersigned, all of the obligations of the undersigned of the Company under this
instrument shall terminate on the effective date of any such determination by the Committee. Any
determination made by the Committee with respect to any such application by the undersigned shall
be conclusive and binding upon both the Company and the undersigned.

The obligations of the undersigned hereunder shall expire in any event five (5) years from the date
hereof.

This instrument shall be construed in accordance with the laws of the Commonwealth of Massachusetts
and shall take effect as an instrument under seal as of the day and year shown below.

	 	 	 	 	 
	DATE:
	 	 	 	 
	 	 	

	

	 	By:<PAGE>
                                                                    EXHIBIT 10.1

                              SETTLEMENT AGREEMENT

                                     between

                       NETWORK HEALTHCARE HOLDINGS LIMITED
                                   ("Netcare")

                                       and

                      TSHEPO PHARMACEUTICALS (PTY) LIMITED
                                   ("Tshepo")

                       (collectively the "Tshepo Parties")

                                       and

                               BIOPURE CORPORATION
     (a company registered in Massachusetts in the United States of America)
                                   ("Biopure")

<PAGE>
                                                                          Page 2

1.         DEFINITIONS

           For the purposes of this Agreement:

1.1        "Affiliate"                        means any person controlling,
                                              controlled by or under common
                                              control with another person, where
                                              "person means any individual or
                                              entity (including but not limited
                                              to any company, corporation,
                                              partnership or unincorporated
                                              association). Affiliates of the
                                              Tshepo Parties shall include, but
                                              not necessarily be limited to
                                              Scanix Six (Pty) Ltd, Malesela
                                              Group (Pty) Ltd, Superbia Three
                                              (Pty) Ltd, Joe Madungandaba and
                                              Anna Mokgokong.

1.2        "the Action"                       means the court action instituted
                                              by Tshepo against Biopure in the
                                              Transvaal Provincial Division of
                                              the High Court of South Africa
                                              under case number 12450/2004.

1.3        "the Distribution Agreement"       means both the sole distributor
                                              agreement entered into between
                                              Netcare and Biopure on 31 July
                                              2000 and the amendment to that
                                              agreement entered into between
                                              Netcare, Biopure and Tshepo on 9
                                              March 2001.

1.4        "the Parties"                      means the signatories hereto, as
                                              well their Affiliates.

1.5        "the Product"                      means Hemopure being a medicine
                                              registered with the Medicines
                                              Control Council of the Republic of
                                              South Africa under reference
                                              number 34/30.4/0261

1.6        "the Registration"                 means the registration of the
                                              Product with the Medicines Control
                                              Council of the Republic of South
                                              Africa under reference number
                                              34/30.4/0261, as well as any
                                              pending or granted registrations
                                              in other African countries in
                                              respect of the Product.

1.7        "the Shares"                       means one million six hundred
                                              thousand shares of Biopure common
                                              stock.

2.         SETTLEMENT

           The Parties record that this agreement is in full and final
           settlement of all claims and disputes between them as set out in more
           detail in clause 6 hereof.

3.         BIOPURE OBLIGATIONS

3.1        Within 3 (three) days following the execution and delivery of this
           Agreement, Biopure shall pay to Netcare acting as agent on behalf of
           Tshepo the amount of US$ 250,000,00 (two hundred and fifty thousand
           US dollars), it being recorded that this payment is in respect of the
           settling of the claims in this Action.
<PAGE>
                                                                          Page 3

3.2        Within 5 (five) days following compliance by Tshepo of its
           obligations in terms of clause 4.1 hereof, Biopure shall cause the
           Shares to be issued and delivered to Tshepo or its nominees, it being
           recorded that the issue and delivery to Tshepo of the Shares is in
           consideration of the termination of the Distribution Agreement and
           being in fulfillment of Biopure's obligation, as previously agreed,
           to furnish stock options to Tshepo.

4.         OBLIGATIONS OF TSHEPO

4.1        Within 5 (five) days following a request in writing from Biopure
           after the compliance by Biopure of all its obligations in clause 3.1
           hereof, Tshepo shall:

           4.1.1     execute and deliver all instruments and documents
                     reasonably required and prepared by Biopure to effect
                     transfer of the Registration to Biopure or its nominee;

           4.1.2     hand over to Biopure all correspondence with the Medicines
                     Control Council and third parties, applications and
                     dossiers for registration in other African countries,
                     agreements, licenses, importation and distribution records,
                     and other documents, in respect of the Product to Biopure.

           4.1.3     hand over to Biopure the original registration certificate
                     and original dossier and amendments thereto in respect of
                     the Registration.

4.2        Tshepo shall deliver a notice of withdrawal of the Action immediately
           following compliance by Biopure of its obligation in clause 3.1.

5.         THE DISTRIBUTION AGREEMENT

           The parties record that the Distribution Agreement terminated with
           effect from 1 June 2004.

6.         FULL SETTLEMENT AND RELEASE

6.1        Subject only to the provisions of clause 6 of this Settlement
           Agreement, the Tshepo Parties and their predecessors, successors,
           Affiliates and assigns (the "Tshepo Releasors") jointly and severally
           as the case may be, upon fulfilment by Biopure of its obligations in
           terms of clause 3 hereof, release and forever fully discharge Biopure
           and its predecessors, successors and assigns, as well as each of its
           and their respective officers, directors, agents, employees,
           attorneys, shareholders, parents, subsidiaries, predecessors,
           successors and assigns (collectively, the "Biopure Releasees") from
           any and all past, present and future payment obligations,
           adjustments, executions, offsets, dues, commissions, salvage, and
           from any and all actions including the Action, causes of action,
           claims, counterclaims, suits, debts, sums of money, accounts,
           covenants, contracts, agreements, promises, contribution,
           indemnification, damages, judgments, executions and demands
           whatsoever, at law, in equity or otherwise, which the Tshepo
           Releasors, or any of them, now or hereafter can, shall or may have
           against Biopure Releasees, or any of them, arising out of any act,
           omission, event or any other thing prior and up to the date of this
           Settlement Agreement, it being understood that the Parties have taken
           into account the possibility that each may hereafter discover facts
           in addition to those now known or suspected.

<PAGE>
                                                                          Page 4

6.2        Subject only to the provisions of clause 6 of this Settlement
           Agreement, Biopure and its predecessors, successors, Affiliates and
           assigns (the "Biopure Releasors"), jointly and severally as the case
           may be, upon fulfilment by Tshepo of its obligations in terms of
           clause 4 hereof, release and forever fully discharge each of the
           Tshepo Parties and their respective predecessors, successors and
           assigns, as well as each of their respective officers, directors,
           agents, employees, attorneys, shareholders, parents, subsidiaries,
           predecessors, successors and assigns (collectively, the "Tshepo
           Releasees") from any and all past, present and future payment
           obligations, adjustments, executions, offsets, dues, commissions,
           salvage, and from any and all actions, causes of action, claims,
           counterclaims, suits, debts, sums of money, accounts, covenants,
           contracts, agreements, promises, contribution, indemnification,
           damages, judgments, executions and demands whatsoever, at law, in
           equity or otherwise, which the Biopure Releasors, or any of them, now
           or hereafter can, shall or may have against Tshepo Releasees, or any
           of them, arising out of any act, omission, event or any other thing
           prior and up to the date of this Settlement Agreement, it being
           understood that the Parties have taken into account the possibility
           that each may hereafter discover facts in addition to those now known
           or suspected.

7.         GENERAL

7.1        This Agreement shall be interpreted in accordance with the laws of
           the Republic of South Africa without regard to principles of
           conflicts of law of any other jurisdiction.

7.2        Each of the Parties consents to the non-exclusive jurisdiction of the
           High Court of South Africa for all purposes under or pursuant to this
           Agreement and to all appeal courts therefrom.

7.3        None of the Parties shall be entitled to cede any of its rights or
           delegate any of its obligations in terms of this Agreement.

7.4        NO ADMISSIONS: Each of the Parties acknowledges and agrees that the
           negotiation, execution and the terms and conditions of this
           Settlement Agreement shall not be considered or deemed admissions by
           any Party concerning any claims, defences or counterclaims of any
           Party, and no past or present liability or wrongdoing on the part of
           any Party shall be implied by the same.

7.5        ENTIRE AGREEMENT: This Settlement Agreement constitutes the entire
           agreement by and between the Tshepo Parties and Biopure with respect
           to the subject matter hereof and supersedes any and all prior
           agreements or understandings concerning such subject matter. Without
           in any way limiting the generality of the foregoing sentence, each
           Party hereby acknowledges, represents and agrees that, in entering
           into this Settlement Agreement, such Party has not relied upon any
           statement, whether written or oral, other than those expressly set
           forth in this Settlement Agreement.

7.6        MISCELLANEOUS: No provision of this Settlement Agreement can be
           changed, waived, discharged or terminated except by an instrument in
           writing signed by each Party expressly referring to the provision of
           this Settlement Agreement to which such instrument relates. This
           Settlement Agreement may be executed simultaneously or in any number
           of actual or facsimile counterparts, each of which shall be deemed an
           original, and which together shall constitute one and the same
           instrument.

8.         REPRESENTATIONS & WARRANTIES:

<PAGE>
                                                                          Page 5

Each Party represents and warrants for itself:

8.1        it has not assigned or transferred, or purported to assign or
           transfer, to any person or entity any claim or cause of action
           released in clause 6 of this Settlement Agreement;

8.2        there are no liens, or claims of lien, or assignments in law or
           equity, or otherwise, of or against any of the claims or causes of
           action being released pursuant to clause 6 of this Settlement
           Agreement;

8.3        each is fully authorized and entitled to enter into this Settlement
           Agreement and every term hereof;

8.4        this Settlement Agreement is a legal, valid and binding obligation of
           such Party, enforceable against such Party in accordance with the
           terms of this Settlement Agreement;

8.5        there are no pending agreements, transactions or negotiations by
           which any Party is bound that would render this Settlement Agreement
           or any part thereof void, voidable or unenforceable;

8.6        each of the Parties enters into this Settlement Agreement freely,
           without coercion, and based on each of the Parties' own judgment and
           not in reliance upon any representations or promises made by any of
           the other Parties, apart from those expressly set forth in this
           Settlement Agreement; and

8.7        each of the Parties has been represented by legal counsel in the
           negotiation and joint preparation of this Settlement Agreement, has
           received advice from legal counsel in connection with this Settlement
           Agreement and is fully aware of this Settlement Agreement's
           provisions and legal effect.

SIGNED at Sandton on 21 January 2005.

                                       For : NETWORK HEALTHCARE HOLDINGS LIMITED

                                             /s/ Michael Sacks
                                         ---------------------------------------
                                             Signatory :   I. Michael Sacks
                                             Capacity :    Chairman
                                             Authority :   Duly authorized

SIGNED at Sandton on 21 January 2005.

                                       For : TSHEPO PHARMACEUTICALS (PTY) LTD

                                             /s/ Michael Sacks
                                         ---------------------------------------
                                             Signatory :   I. Michael Sacks
                                             Capacity :    Authorized Signatory
                                             Authority :   Duly authorized

<PAGE>
                                                                          Page 6

SIGNED at Cambridge on January 21, 2005.

                                         For : BIOPURE CORPORATION

                                               /s/ Zafiris G. Zafirelis
                                         --------------------------------------
                                               Signatory :
                                               Capacity :
                                               Authority :

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]